2011
DOI: 10.1016/j.ccr.2011.01.035
|View full text |Cite
|
Sign up to set email alerts
|

The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma

Abstract: SUMMARY High-grade gliomas are notoriously insensitive to radiation and genotoxic drugs. Paradoxically, the p53 gene is structurally intact in the majority of these tumors. Resistance to genotoxic modalities in p53-positive gliomas is generally attributed to attenuation of p53 functions by mutations of other components within the p53 signaling axis, such as p14Arf, MDM2 and ATM, but this explanation is not entirely satisfactory. We show here that the central nervous system (CNS) restricted transcription factor… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

16
169
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 142 publications
(185 citation statements)
references
References 72 publications
(102 reference statements)
16
169
0
Order By: Relevance
“…OLIG2 also appears to directly activate another set of genes, including several core cell cycle regulators, and by this means promotes NS cell proliferation. The contribution of Olig2 to the proliferation of both normal and malignant neural progenitors has been described previously, although this work has focused on OLIG2's antagonism of Cdkn1a (also OLIG2-bound here) and the p53 pathway (Ligon et al 2007;Mehta et al 2011;Sun et al 2011b), rather than the novel functions in directly inducing cell cycle activators and repressing quiescence genes that we describe here. It will be interesting to determine how previously described post-translational mechanisms such as phosphorylation of key residues of OLIG2 (Li et al 2011a;Sun et al 2011b) and interactions with TRP53 protein (Mehta et al 2011) combine with chromatin-level epigenetic and co-factor-mediated mechanisms described here to explain how OLIG2 can be directed toward such context-specific functions to both activate and repress target gene expression.…”
Section: Olig2 Is a Multifunctional Regulator Of Ns Cell Self-renewalmentioning
confidence: 97%
“…OLIG2 also appears to directly activate another set of genes, including several core cell cycle regulators, and by this means promotes NS cell proliferation. The contribution of Olig2 to the proliferation of both normal and malignant neural progenitors has been described previously, although this work has focused on OLIG2's antagonism of Cdkn1a (also OLIG2-bound here) and the p53 pathway (Ligon et al 2007;Mehta et al 2011;Sun et al 2011b), rather than the novel functions in directly inducing cell cycle activators and repressing quiescence genes that we describe here. It will be interesting to determine how previously described post-translational mechanisms such as phosphorylation of key residues of OLIG2 (Li et al 2011a;Sun et al 2011b) and interactions with TRP53 protein (Mehta et al 2011) combine with chromatin-level epigenetic and co-factor-mediated mechanisms described here to explain how OLIG2 can be directed toward such context-specific functions to both activate and repress target gene expression.…”
Section: Olig2 Is a Multifunctional Regulator Of Ns Cell Self-renewalmentioning
confidence: 97%
“…S8). Pten/Rb tumor grafts strongly express olig2, offering a possible explanation for a selective downregulation of p53 function in the absence of a genetic mutation (51).…”
Section: Discussionmentioning
confidence: 99%
“…These include oligodendrocytes precursor cells (OPCs), which are destined to give rise to the cells that form the insulating myelin sheet around nerve fibers. OPCs are characterized by the expression of the transcription factor Olig-2 that represses the p53 tumor suppression pathway, allowing cells to continue dividing postnatally [2]. Consequently, these Olig-2-expressing cells have a heightened susceptibility to cancers as a result of somatic mutations in oncogenes.…”
mentioning
confidence: 99%